REFERENCES
1. Cunha GR, Donjacour AA, Cooke PS, et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987;8:338-62.
2. Kumar VL, Majumder PK. Prostate gland: structure, functions and regulation. Int Urol Nephrol 1995;27:231-43.
3. Singh O, Bolla SR. Anatomy, abdomen and pelvis, prostate. Treasure Island: StatPearls; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK540987/ [Last accessed on 22 Jul 2024].
5. Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer. Semin Oncol 2013;40:244-58.
7. Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis 2024;27:192-201.
8. Krušlin B, Ulamec M, Tomas D. Prostate cancer stroma: an important factor in cancer growth and progression. Bosn J Basic Med Sci 2015;15:1-8.
9. Levesque C, Nelson PS. Cellular constituents of the prostate stroma: key contributors to prostate cancer progression and therapy resistance. CSH Perspect Med 2018;8:a030510.
10. Pederzoli F, Raffo M, Pakula H, Ravera F, Nuzzo PV, Loda M. Stromal cells in prostate cancer pathobiology: friends or foes? Br J Cancer 2023;128:930-9.
11. Barron DA, Rowley DR. The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer 2012;19:R187-204.
12. Davey RA, Grossmann M. Androgen receptor structure, function and biology: from bench to bedside. Clin Biochem Rev 2016;37:3-15.
13. Wen S, Chang HC, Tian J, Shang Z, Niu Y, Chang C. Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer. Am J Pathol 2015;185:293-301.
14. Cunha GR. Epithelio-mesenchymal interactions in primordial gland structures which become responsive to androgenic stimulation. Anat Rec 1972;172:179-95.
15. Schauer IG, Rowley DR. The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation 2011;82:200-10.
16. Schauer IG, Ressler SJ, Tuxhorn JA, Dang TD, Rowley DR. Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology 2008;72:205-13.
17. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002;8:2912-23.
18. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001;166:2472-83.
19. Kai F, Drain AP, Weaver VM. The extracellular matrix modulates the metastatic journey. Dev Cell 2019;49:332-46.
20. Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol 2018;15:366-81.
21. Puré E, Lo A. Can targeting stroma pave the way to enhanced antitumor immunity and immunotherapy of solid tumors? Cancer Immunol Res 2016;4:269-78.
22. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423-37.
23. Xiao Z, Todd L, Huang L, et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat Commun 2023;14:5110.
24. Zhang FF, Qiao Y, Xie Y, et al. Epitope-based minigene vaccine targeting fibroblast activation protein α induces specific immune responses and anti-tumor effects in 4 T1 murine breast cancer model. Int Immunopharmacol 2022;112:109237.
25. Gorbach IN, Novikov DK. [Detection of leukocyte sensitization to tuberculosis mycobacterial antigens in newborns by the method of migration suppression in vitro]. Vopr Okhr Materin Det 1976;21:66-8.
26. Giacomini A, Grillo E, Rezzola S, et al. The FGF/FGFR system in the physiopathology of the prostate gland. Physiol Rev 2021;101:569-610.
27. Cunha GR. Mesenchymal-epithelial interactions: past, present, and future. Differentiation 2008;76:578-86.
28. Roberson KM, Edwards DW, Chang GC, Robertson CN. Isolation and characterization of a novel human prostatic stromal cell culture: DuK50. In Vitro Cell Dev Biol Anim 1995;31:840-5.
29. Webber MM, Trakul N, Thraves PS, et al. A human prostatic stromal myofibroblast cell line WPMY-1: a model for stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis 1999;20:1185-92.
30. Simons BW, Hurley PJ, Huang Z, et al. Wnt signaling though beta-catenin is required for prostate lineage specification. Dev Biol 2012;371:246-55.
32. Mostofi FK, Sesterhenn IA, Davis CJ. A pathologist's view of prostatic carcinoma. Cancer 1993;71:906-32.
33. Steukers L, Glorieux S, Vandekerckhove AP, Favoreel HW, Nauwynck HJ. Diverse microbial interactions with the basement membrane barrier. Trends Microbiol 2012;20:147-55.
34. Brekken RA, Stupack D. Extracellular matrix in tumor biology. In: Biology of extracellular matrix. Cham: Springer International Publishing; 2017.
35. Welén K, Damber JE. Androgens, aging, and prostate health. Rev Endocr Metab Disord 2022;23:1221-31.
36. Stanworth RD, Jones TH. Testosterone for the aging male; current evidence and recommended practice. Clin Interv Aging 2008;3:25-44.
37. Prins GS, Huang L, Birch L, Pu Y. The role of estrogens in normal and abnormal development of the prostate gland. Ann N Y Acad Sci 2006;1089:1-13.
38. Shapiro E, Huang H, Masch RJ, McFadden DE, Wilson EL, Wu XR. Immunolocalization of estrogen receptor alpha and beta in human fetal prostate. J Urol 2005;174:2051-3.
39. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008;73:233-44.
40. Coffey DS, Walsh PC. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990;17:461-75.
41. Vickman RE, Franco OE, Moline DC, Vander Griend DJ, Thumbikat P, Hayward SW. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: a review. Asian J Urol 2020;7:191-202.
42. Schulze H, Claus S. Histological localization of estrogen receptors in normal and diseased human prostates by immunocytochemistry. Prostate 1990;16:331-43.
43. Schulze H, Barrack ER. Immunocytochemical localization of estrogen receptors in the normal male and female canine urinary tract and prostate. Endocrinology 1987;121:1773-83.
44. Prins GS, Birch L. Neonatal estrogen exposure up-regulates estrogen receptor expression in the developing and adult rat prostate lobes. Endocrinology 1997;138:1801-9.
45. Yu Y, Liu L, Xie N, et al. Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control. J Clin Endocrinol Metab 2013;98:2887-96.
46. Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013;155:1309-22.
47. Tuong ZK, Loudon KW, Berry B, et al. Resolving the immune landscape of human prostate at a single-cell level in health and cancer. Cell Rep 2021;37:110132.
48. Henry GH, Malewska A, Joseph DB, et al. A cellular anatomy of the normal adult human prostate and prostatic urethra. Cell Rep 2018;25:3530-3542.e5.
49. Mass E, Ballesteros I, Farlik M, et al. Specification of tissue-resident macrophages during organogenesis. Science 2016;353:aaf4238.
50. Costello LC, Franklin RB. A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer. Arch Biochem Biophys 2016;611:100-12.
51. Singh KK, Desouki MM, Franklin RB, Costello LC. Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol Cancer 2006;5:14.
52. Ginhoux F, Guilliams M. Tissue-resident macrophage ontogeny and homeostasis. Immunity 2016;44:439-49.
53. Cannarella R, Condorelli RA, Barbagallo F, La Vignera S, Calogero AE. Endocrinology of the aging prostate: current concepts. Front Endocrinol 2021;12:554078.
54. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589-98.
55. O'Donnell AB, Araujo AB, McKinlay JB. The health of normally aging men: The massachusetts male aging study (1987-2004). Exp Gerontol 2004;39:975-84.
56. Huhtaniemi I. Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment. Asian J Androl 2014;16:192-202.
57. Rastrelli G, Vignozzi L, Corona G, Maggi M. Testosterone and benign prostatic hyperplasia. Sex Med Rev 2019;7:259-71.
58. Vignozzi L, Cellai I, Santi R, et al. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol 2012;214:31-43.
59. Ho CH, Fan CK, Yu HJ, et al. Testosterone suppresses uropathogenic escherichia coli invasion and colonization within prostate cells and inhibits inflammatory responses through JAK/STAT-1 signaling pathway. PLoS One 2017;12:e0180244.
60. Quintar AA, Gonçalves BF, Taboga SR, Maldonado CA. The mongolian gerbil (meriones unguiculatus) as a model for inflammation-promoted prostate carcinogenesis. Cell Biol Int 2017;41:1234-8.
61. Cohen PG. Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis. Med Hypotheses 2008;70:358-60.
62. Yang Y, Sheng J, Hu S, et al. Estrogen and G protein-coupled estrogen receptor accelerate the progression of benign prostatic hyperplasia by inducing prostatic fibrosis. Cell Death Dis 2022;13:533.
63. Ellem SJ, Risbridger GP. Aromatase and regulating the estrogen: androgen ratio in the prostate gland. J Steroid Biochem Mol Biol 2010;118:246-51.
64. Rebbeck TR. Prostate cancer disparities by race and ethnicity: from nucleotide to neighborhood. Cold Spring Harb Perspect Med 2018;8:a030387.
65. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021;71:7-33.
66. Chowdhury-Paulino IM, Ericsson C, Vince R Jr, Spratt DE, George DJ, Mucci LA. Racial disparities in prostate cancer among black men: epidemiology and outcomes. Prostate Cancer Prostatic Dis 2022;25:397-402.
67. Hinata N, Fujisawa M. Racial differences in prostate cancer characteristics and cancer-specific mortality: an overview. World J Mens Health 2022;40:217-27.
68. Rohrmann S, Nelson WG, Rifai N, et al. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab 2007;92:2519-25.
69. Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL. The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer 1988;57:216-8.
70. Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 2004;92:237-53.
71. Giusti RM, Iwamoto K, Hatch EE. Diethylstilbestrol revisited: a review of the long-term health effects. Ann Intern Med 1995;122:778-88.
72. Fox JJ, Hashimoto T, Navarro HI, Garcia AJ, Shou BL, Goldstein AS. Highly multiplexed immune profiling throughout adulthood reveals kinetics of lymphocyte infiltration in the aging mouse prostate. Aging 2023;15:3356-80.
73. Khan D, Ansar Ahmed S. The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases. Front Immunol 2015;6:635.
74. Eifert C, Powers RS. From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer 2012;12:572-8.
75. Dotto GP. Multifocal epithelial tumors and field cancerization: stroma as a primary determinant. J Clin Invest 2014;124:1446-53.
76. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 2003;107:1-10.
77. Cunha GR, Hayward SW, Wang YZ. Role of stroma in carcinogenesis of the prostate. Differentiation 2002;70:473-85.
78. Wang Y, Sudilovsky D, Zhang B, et al. A human prostatic epithelial model of hormonal carcinogenesis. Cancer Res 2001;61:6064-72.
79. Ricke WA, Ishii K, Ricke EA, et al. Steroid hormones stimulate human prostate cancer progression and metastasis. Int J Cancer 2006;118:2123-31.
80. Hayward SW, Wang Y, Cao M, et al. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 2001;61:8135-42.
81. Hu B, Castillo E, Harewood L, et al. Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell 2012;149:1207-20.
82. Salem AF, Al-Zoubi MS, Whitaker-Menezes D, et al. Cigarette smoke metabolically promotes cancer, via autophagy and premature aging in the host stromal microenvironment. Cell Cycle 2013;12:818-25.
83. Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013;499:97-101.
84. Berglund E, Maaskola J, Schultz N, et al. Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity. Nat Commun 2018;9:2419.
85. Kwon OJ, Zhang Y, Li Y, et al. Functional heterogeneity of mouse prostate stromal cells revealed by single-cell RNA-Seq. iScience 2019;13:328-38.
86. Huet E, Jaroz C, Nguyen HQ, et al. Stroma in normal and cancer wound healing. FEBS J 2019;286:2909-20.
87. Varga J, Brenner DA, Phan SH. Fibrosis research: methods and protocols. Berlin: Springer; 2008.
89. Schäfer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 2008;9:628-38.
90. Haddow A. Molecular repair, wound healing, and carcinogenesis: tumor production a possible overhealing? Amsterdam: Elsevier; 1973. pp. 181-234.
91. Langley RR, Fidler IJ. The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011;128:2527-35.
92. Plava J, Cihova M, Burikova M, Matuskova M, Kucerova L, Miklikova S. Recent advances in understanding tumor stroma-mediated chemoresistance in breast cancer. Mol Cancer 2019;18:67.
93. Mesker WE, Junggeburt JM, Szuhai K, et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol 2007;29:387-98.
94. Almangush A, Alabi RO, Troiano G, et al. Clinical significance of tumor-stroma ratio in head and neck cancer: a systematic review and meta-analysis. BMC Cancer 2021;21:480.
95. He R, Li D, Liu B, et al. The prognostic value of tumor-stromal ratio combined with TNM staging system in esophagus squamous cell carcinoma. J Cancer 2021;12:1105-14.
96. Zhu Y, Jin Z, Qian Y, Shen Y, Wang Z. Prognostic value of tumor-stroma ratio in rectal cancer: a systematic review and meta-analysis. Front Oncol 2021;11:685570.
97. Ruder S, Gao Y, Ding Y, et al. Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis. Hum Pathol 2022;122:84-91.
98. Ayala G, Tuxhorn JA, Wheeler TM, et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 2003;9:4792-801.
99. Tran LL, Dang T, Thomas R, Rowley DR. ELF3 mediates IL-1α induced differentiation of mesenchymal stem cells to inflammatory iCAFs. Stem Cells 2021;39:1766-77.
100. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999;59:5002-11.
101. Hayashi N, Cunha GR. Mesenchyme-induced changes in the neoplastic characteristics of the Dunning prostatic adenocarcinoma. Cancer Res 1991;51:4924-30.
103. Mun JY, Leem SH, Lee JH, Kim HS. Dual relationship between stromal cells and immune cells in the tumor microenvironment. Front Immunol 2022;13:864739.
104. Sanjabi S, Oh SA, Li MO. Regulation of the immune response by TGF-β: from conception to autoimmunity and infection. Cold Spring Harb Perspect Biol 2017;9:a022236.
105. Zhang F, Wang H, Wang X, et al. TGF-β induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype. Oncotarget 2016;7:52294-306.
106. Penn JW, Grobbelaar AO, Rolfe KJ. The role of the TGF-beta family in wound healing, burns and scarring: a review. Int J Burns Trauma 2012;2:18-28.
107. Zhang Y, Alexander PB, Wang XF. TGF-β family signaling in the control of cell proliferation and survival. Cold Spring Harb Perspect Biol 2017;9:a022145.
108. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009;19:156-72.
109. Farooq M, Khan AW, Kim MS, Choi S. The role of fibroblast growth factor (FGF) signaling in tissue repair and regeneration. Cells 2021;10:3242.
110. Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Role of platelet-derived growth factor in wound healing. J Cell Biochem 1991;45:319-26.
111. Diller RB, Tabor AJ. The role of the extracellular matrix (ECM) in wound healing: a review. Biomimetics 2022;7:87.
112. Rodriguez-Pascual F, Rosell-Garcia T. Lysyl oxidases: functions and disorders. J Glaucoma 2018;27 Suppl 1:S15-9.
113. Wang LC, Lo A, Scholler J, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2014;2:154-66.
114. Nissen NI, Karsdal M, Willumsen N. Collagens and cancer associated fibroblasts in the reactive stroma and its relation to cancer biology. J Exp Clin Cancer Res 2019;38:115.
115. Henke E, Nandigama R, Ergün S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci 2019;6:160.
117. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag 2006;2:213-9.
118. Li Y, Zhao L, Li XF. Hypoxia and the tumor microenvironment. Technol Cancer Res Treat 2021;20:15330338211036304.
119. Zhang Y, Coleman M, Brekken RA. Perspectives on hypoxia signaling in tumor stroma. Cancers 2021;13:3070.
120. Crola Da Silva C, Lamerant-Fayel N, Paprocka M, et al. Selective human endothelial cell activation by chemokines as a guide to cell homing. Immunology 2009;126:394-404.
121. Crowley T, Buckley CD, Clark AR. Stroma: the forgotten cells of innate immune memory. Clin Exp Immunol 2018;193:24-36.
122. Jiang Z, Zhou J, Li L, et al. Pericytes in the tumor microenvironment. Cancer Lett 2023;556:216074.
123. Thomas H, Cowin AJ, Mills SJ. The importance of pericytes in healing: wounds and other pathologies. Int J Mol Sci 2017;18:1129.
124. Paiva AE, Lousado L, Guerra DAP, et al. Pericytes in the premetastatic niche. Cancer Res 2018;78:2779-86.
125. Kirk T, Ahmed A, Rognoni E. Fibroblast memory in development, homeostasis and disease. Cells 2021;10:2840.
126. Netea MG, Quintin J, van der Meer JW. Trained immunity: a memory for innate host defense. Cell Host Microbe 2011;9:355-61.
127. Wang T, Hu Y, Dusi S, et al. "Open Sesame" to the complexity of pattern recognition receptors of myeloid-derived suppressor cells in cancer. Front Immunol 2023;14:1130060.
128. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801.
129. Netea MG, van der Meer JW. Trained immunity: an ancient way of remembering. Cell Host Microbe 2017;21:297-300.
130. Dakin SG, Buckley CD, Al-Mossawi MH, et al. Persistent stromal fibroblast activation is present in chronic tendinopathy. Arthritis Res Ther 2017;19:16.
131. Klein K, Frank-Bertoncelj M, Karouzakis E, et al. The epigenetic architecture at gene promoters determines cell type-specific LPS tolerance. J Autoimmun 2017;83:122-33.
132. Sohn C, Lee A, Qiao Y, Loupasakis K, Ivashkiv LB, Kalliolias GD. Prolonged tumor necrosis factor α primes fibroblast-like synoviocytes in a gene-specific manner by altering chromatin. Arthritis Rheumatol 2015;67:86-95.
133. Koch SR, Lamb FS, Hellman J, Sherwood ER, Stark RJ. Potentiation and tolerance of toll-like receptor priming in human endothelial cells. Transl Res 2017;180:53-67.e4.
134. Naik S, Larsen SB, Gomez NC, et al. Author correction: inflammatory memory sensitizes skin epithelial stem cells to tissue damage. Nature 2018;560:E2.
135. Ara T, Kurata K, Hirai K, et al. Human gingival fibroblasts are critical in sustaining inflammation in periodontal disease. J Periodontal Res 2009;44:21-7.
136. Lee A, Qiao Y, Grigoriev G, et al. Tumor necrosis factor α induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2013;65:928-38.
137. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-14.
138. Wolff B, Burns AR, Middleton J, Rot A. Endothelial cell "memory" of inflammatory stimulation: human venular endothelial cells store interleukin 8 in Weibel-Palade bodies. J Exp Med 1998;188:1757-62.
139. Bonfanti R, Furie BC, Furie B, Wagner DD. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood 1989;73:1109-12.
140. McEver RP, Beckstead JH, Moore KL, Marshall-Carlson L, Bainton DF. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 1989;84:92-9.
141. Zimmerman GA, McIntyre TM, Mehra M, Prescott SM. Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. J Cell Biol 1990;110:529-40.
142. Séguin C, Abid MR, Spokes KC, et al. Priming effect of homocysteine on inducible vascular cell adhesion molecule-1 expression in endothelial cells. Biomed Pharmacother 2008;62:395-400.
143. Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: the "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009;94:410-5.
144. Testa R, Bonfigli AR, Prattichizzo F, La Sala L, De Nigris V, Ceriello A. The "Metabolic Memory" theory and the early treatment of hyperglycemia in prevention of diabetic complications. Nutrients 2017;9:437.
145. Yao Y, Song Q, Hu C, et al. Endothelial cell metabolic memory causes cardiovascular dysfunction in diabetes. Cardiovasc Res 2022;118:196-211.
146. Muhl L, Genové G, Leptidis S, et al. Single-cell analysis uncovers fibroblast heterogeneity and criteria for fibroblast and mural cell identification and discrimination. Nat Commun 2020;11:3953.
147. Amersfoort J, Eelen G, Carmeliet P. Immunomodulation by endothelial cells - partnering up with the immune system? Nat Rev Immunol 2022;22:576-88.
148. Yeo SY, Lee KW, Shin D, An S, Cho KH, Kim SH. A positive feedback loop bi-stably activates fibroblasts. Nat Commun 2018;9:3016.
150. Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 2012;4:127ps8.
151. Lin R, Zhang C, Zheng J, et al. Chronic inflammation-associated genomic instability paves the way for human esophageal carcinogenesis. Oncotarget 2016;7:24564-71.
152. Hibino S, Kawazoe T, Kasahara H, et al. Inflammation-induced tumorigenesis and metastasis. Int J Mol Sci 2021;22:5421.
153. Bockerstett KA, DiPaolo RJ. Regulation of gastric carcinogenesis by inflammatory cytokines. Cell Mol Gastroenter Hepatol 2017;4:47-53.
154. Qian S, Golubnitschaja O, Zhan X. Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA J 2019;10:365-81.
155. He S, Xu J, Liu X, Zhen Y. Advances and challenges in the treatment of esophageal cancer. Acta Pharm Sin B 2021;11:3379-92.
156. Ashrafi A, Akter Z, Modareszadeh P, et al. Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance. Cancers 2022;14:4562.
157. Marin JJ, Al-Abdulla R, Lozano E, et al. Mechanisms of resistance to chemotherapy in gastric cancer. Anti Agent Med Chem 2016;16:318-34.
158. Wang Q, Shen X, Chen G, Du J. Drug resistance in colorectal cancer: from mechanism to clinic. Cancers 2022;14:2928.
159. Scott AK, Rafuse M, Neu CP. Mechanically induced alterations in chromatin architecture guide the balance between cell plasticity and mechanical memory. Front Cell Dev Biol 2023;11:1084759.
161. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
166. Pham SM, Kormos RL, Landreneau RJ, et al. Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg 1995;60:1623-6.
167. Nair SS, Weil R, Dovey Z, Davis A, Tewari AK. The tumor microenvironment and immunotherapy in prostate and bladder cancer. Urol Clin North Am 2020;47:e17-54.
168. Zhong C, Li Y, Yang J, et al. Immunotherapy for hepatocellular carcinoma: current limits and prospects. Front Oncol 2021;11:589680.
169. Jia D, Zhou Z, Kwon OJ, et al. Stromal FOXF2 suppresses prostate cancer progression and metastasis by enhancing antitumor immunity. Nat Commun 2022;13:6828.
170. Lander VE, Belle JI, Kingston NL, et al. Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade. Cancer Discov 2022;12:2774-99.
171. Yang D, Duan MH, Yuan QE, et al. Suppressive stroma-immune prognostic signature impedes immunotherapy in ovarian cancer and can be reversed by PDGFRB inhibitors. J Transl Med 2023;21:586.
172. Bremnes RM, Dønnem T, Al-Saad S, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 2011;6:209-17.
173. Nishikawa H, Koyama S. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Cancer 2021;9:e002591.
174. Lunardi S, Jamieson NB, Lim SY, et al. IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Oncotarget 2014;5:11064-80.
175. Vilgelm AE, Richmond A. Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy. Front Immunol 2019;10:333.
176. Hussain S, Peng B, Cherian M, Song JW, Ahirwar DK, Ganju RK. The roles of stroma-derived chemokine in different stages of cancer metastases. Front Immunol 2020;11:598532.
177. Deng J, Jiang R, Meng E, Wu H. CXCL5: a coachman to drive cancer progression. Front Oncol 2022;12:944494.
178. Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010;330:827-30.
179. Poznansky MC, Olszak IT, Foxall R, Evans RH, Luster AD, Scadden DT. Active movement of T cells away from a chemokine. Nat Med 2000;6:543-8.
180. Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007;292:C987-95.
182. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010;31:220-7.
183. Shi X, Young CD, Zhou H, Wang X. Transforming growth factor-β signaling in fibrotic diseases and cancer-associated fibroblasts. Biomolecules 2020;10:1666.
184. Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 2018;554:544-8.
185. Zippi M, De Toma G, Minervini G, et al. Desmoplasia influenced recurrence of disease and mortality in stage III colorectal cancer within five years after surgery and adjuvant therapy. Saudi J Gastroenterol 2017;23:39-44.
186. Whatcott CJ, Posner RG, Von Hoff DD, Han H. Chapter 8 desmoplasia and chemoresistance in pancreatic cancer. In: Grippo PJ, Munshi HG, editors. Pancreatic cancer and tumor microenvironment. India: Trivandrum; 2012. Available from: https://www.ncbi.nlm.nih.gov/books/NBK98939/ [Last accessed on 22 Jul 2024].
188. González-González L, Alonso J. Periostin: a matricellular protein with multiple functions in cancer development and progression. Front Oncol 2018;8:225.
189. Wei T, Wang K, Liu S, et al. Periostin deficiency reduces PD-1+ tumor-associated macrophage infiltration and enhances anti-PD-1 efficacy in colorectal cancer. Cell Rep 2023;42:112090.
191. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 2019;18:197-218.
192. Hussein MR, Al-Assiri M, Musalam AO. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Exp Mol Pathol 2009;86:108-13.
193. von Amsberg G, Alsdorf W, Karagiannis P, et al. Immunotherapy in advanced prostate cancer-light at the end of the tunnel? Int J Mol Sci 2022;23:2569.
194. Anker JF, Naseem AF, Mok H, Schaeffer AJ, Abdulkadir SA, Thumbikat P. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun 2018;9:1591.
195. Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer 2018;6:157.
196. Wang I, Song L, Wang BY, Rezazadeh Kalebasty A, Uchio E, Zi X. Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy. Am J Clin Exp Urol 2022;10:210-33.
197. Ma Z, Zhang W, Dong B, et al. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Theranostics 2022;12:4965-79.
198. Chesner L, Graff J, Polesso F, et al. Abstract B041: AR suppresses MHC class I expression and T-cell response in prostate cancer. Cancer Res 2023;83:B041.
199. Kogan-Sakin I, Cohen M, Paland N, et al. Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. Carcinogenesis 2009;30:698-705.
200. Tse BW, Scott KF, Russell PJ. Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology. Prostate Cancer 2012;2012:128965.
201. Smith BN, Mishra R, Billet S, et al. Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit. Mol Ther 2023;31:78-89.
202. Zhou C, Gao Y, Ding P, Wu T, Ji G. The role of CXCL family members in different diseases. Cell Death Discov 2023;9:212.
203. Bullock K, Richmond A. Suppressing MDSC recruitment to the tumor microenvironment by antagonizing CXCR2 to enhance the efficacy of immunotherapy. Cancers 2021;13:6293.
204. Korbecki J, Kupnicka P, Chlubek M, Gorący J, Gutowska I, Baranowska-Bosiacka I. CXCR2 receptor: regulation of expression, signal transduction, and involvement in cancer. Int J Mol Sci 2022;23:2168.
205. Di Mitri D, Mirenda M, Vasilevska J, et al. Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer. Cell Rep 2019;28:2156-2168.e5.
206. Bahig H, Taussky D, Delouya G, et al. Neutrophil count is associated with survival in localized prostate cancer. BMC Cancer 2015;15:594.
207. Sharma J, Gray KP, Harshman LC, et al. Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate 2014;74:820-8.
208. Minas TZ, Candia J, Dorsey TH, et al. Serum proteomics links suppression of tumor immunity to ancestry and lethal prostate cancer. Nat Commun 2022;13:1759.
209. Wallace TA, Prueitt RL, Yi M, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008;68:927-36.
210. Zhu W, Wu J, Huang J, et al. Multi-omics analysis reveals a macrophage-related marker gene signature for prognostic prediction, immune landscape, genomic heterogeneity, and drug choices in prostate cancer. Front Immunol 2023;14:1122670.
211. Chen C, Luo J, Wang X. Identification of prostate cancer subtypes based on immune signature scores in bulk and single-cell transcriptomes. Med Oncol 2022;39:123.
212. Guo T, Wang J, Yan S, et al. A combined signature of glycolysis and immune landscape predicts prognosis and therapeutic response in prostate cancer. Front Endocrinol 2022;13:1037099.
213. Ren C, Wang Q, Wang S, et al. Metabolic syndrome-related prognostic index: predicting biochemical recurrence and differentiating between cold and hot tumors in prostate cancer. Front Endocrinol 2023;14:1148117.
214. Li N, Yu K, Lin Z, Zeng D. Development of a novel immune subtyping system expanded with immune landscape and an 11-gene signature for predicting prostate cancer survival. J Oncol 2022;2022:1183173.
215. Keam SP, Halse H, Nguyen T, et al. High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. J Immunother Cancer 2020;8:e000792.
216. Shen Y, Xu H, Long M, et al. Screening to identify an immune landscape-based prognostic predictor and therapeutic target for prostate cancer. Front Oncol 2021;11:761643.
217. Zhang G, Luo Y. An immune-related lncRNA signature to predict the biochemical recurrence and immune landscape in prostate cancer. Int J Gen Med 2021;14:9031-49.
219. Antognelli C, Mandarano M, Prosperi E, Sidoni A, Talesa VN. Glyoxalase-1-dependent methylglyoxal depletion sustains PD-L1 expression in metastatic prostate cancer cells: a novel mechanism in cancer immunosurveillance escape and a potential novel target to overcome PD-L1 blockade resistance. Cancers 2021;13:2965.
220. Datta M, Coussens LM, Nishikawa H, Hodi FS, Jain RK. Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies. Am Soc Clin Oncol Educ Book 2019;39:165-74.
221. Perera MPJ, Thomas PB, Risbridger GP, et al. Chimeric antigen receptor T-cell therapy in metastatic castrate-resistant prostate cancer. Cancers 2022;14:503.
222. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003;30:667-76.
223. Sardinha M, Palma Dos Reis AF, Barreira JV, Fontes Sousa M, Pacey S, Luz R. Antibody-drug conjugates in prostate cancer: a systematic review. Cureus 2023;15:e34490.
224. Kamat NV, Yu EY, Lee JK. BiTE-ing into prostate cancer with bispecific T-cell engagers. Clin Cancer Res 2021;27:2675-7.
225. Yang K, Feng S, Luo Z. Oncolytic adenovirus, a new treatment strategy for prostate cancer. Biomedicines 2022;10:3262.
226. Pieczonka CM, Telonis D, Mouraviev V, Albala D. Sipuleucel-T for the treatment of patients with metastatic castrate-resistant prostate cancer: considerations for clinical practice. Rev Urol 2015;17:203-10.
227. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
228. Donninger H, Li C, Eaton JW, Yaddanapudi K. Cancer vaccines: promising therapeutics or an unattainable dream. Vaccines 2021;9:668.
229. Chen S, Wainwright DA, Wu JD, et al. CD73: an emerging checkpoint for cancer immunotherapy. Immunotherapy 2019;11:983-97.
230. Mbongue JC, Nicholas DA, Torrez TW, Kim NS, Firek AF, Langridge WH. The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity. Vaccines 2015;3:703-29.
231. Solinas C, Migliori E, De Silva P, Willard-Gallo K. LAG3: the biological processes that motivate targeting this immune checkpoint molecule in human cancer. Cancers 2019;11:1213.
232. Miller RA, Luke JJ, Hu S, et al. Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer. J Immunother Cancer 2022;10:e005802.
233. Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med 2014;211:715-25.
234. Fu Y, Lin Q, Zhang Z, Zhang L. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm Sin B 2020;10:414-33.
235. Ye L, Jia K, Wang L, et al. CD137, an attractive candidate for the immunotherapy of lung cancer. Cancer Sci 2020;111:1461-7.
236. Bayer AL, Pugliese A, Malek TR. The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation. Immunol Res 2013;57:197-209.
237. Schepisi G, Cursano MC, Casadei C, et al. CAR-T cell therapy: a potential new strategy against prostate cancer. J Immunother Cancer 2019;7:258.
238. Patel S, Burga RA, Powell AB, et al. Beyond CAR T cells: other cell-based immunotherapeutic strategies against cancer. front oncol 2019;9:196.
239. Mills JK, Henderson MA, Giuffrida L, et al. Generating CAR T cells from tumor-infiltrating lymphocytes. Ther Adv Vaccines Immunother 2021;9:25151355211017119.
240. Zhou B, Lin W, Long Y, et al. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther 2022;7:95.
241. Day KC, Lorenzatti Hiles G, Kozminsky M, et al. HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res 2017;77:74-85.
242. Hsu EC, Rice MA, Bermudez A, et al. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc Natl Acad Sci USA 2020;117:2032-42.
243. Rosellini M, Santoni M, Mollica V, et al. Treating prostate cancer by antibody-drug conjugates. Int J Mol Sci 2021;22:1551.
244. Tian Z, Liu M, Zhang Y, Wang X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol 2021;14:75.
245. Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther 2023;8:156.
246. Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res 2005;65:11156-63.
247. Wen Y, Wang CT, Ma TT, et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci 2010;101:2325-32.
248. Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther 2014;22:102-11.
249. Freedman JD, Duffy MR, Lei-Rossmann J, et al. An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells. Cancer Res 2018;78:6852-65.
250. Chaudary N, Pintilie M, Jelveh S, Lindsay P, Hill RP, Milosevic M. Plerixafor improves primary tumor response and reduces metastases in cervical cancer treated with radio-chemotherapy. Clin Cancer Res 2017;23:1242-9.
251. Kim ST, Hong JY, Park SH, et al. First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. Ther Adv Med Oncol 2020;12:1758835920926796.
252. Zhang X, Luo H. Effects of thalidomide on growth and VEGF-A expression in SW480 colon cancer cells. Oncol Lett 2018;15:3313-20.
253. Pulte ED, Dmytrijuk A, Nie L, et al. FDA approval summary: lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myeloma. Oncologist 2018;23:734-9.
254. Summers J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 2010;15:104-11.
255. Singh AD, Parmar S. Ramucirumab (Cyramza): a breakthrough treatment for gastric cancer. P T 2015;40:430-68.
256. Chiorean EG, Sweeney C, Youssoufian H, et al. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2014;73:595-604.
257. Kwon MJ. Matrix metalloproteinases as therapeutic targets in breast cancer. Front Oncol 2022;12:1108695.
258. Nadal L, Corbellari R, Villa A, et al. Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors in vivo. MAbs 2020;12:1836713.
259. Neesse A, Frese KK, Bapiro TE, et al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci USA 2013;110:12325-30.
260. Ke FY, Chen WY, Lin MC, Hwang YC, Kuo KT, Wu HC. Novel monoclonal antibody against integrin α3 shows therapeutic potential for ovarian cancer. Cancer Sci 2020;111:3478-92.
261. Sun Y, Zhao C, Ye Y, et al. High expression of fibronectin 1 indicates poor prognosis in gastric cancer. Oncol Lett 2020;19:93-102.
262. Streel G, Lucas S. Targeting immunosuppression by TGF-β1 for cancer immunotherapy. Biochem Pharmacol 2021;192:114697.
263. Ma C, Xi S, Sun H, Zhang M, Pei Y. Identifying the oncogenic roles of FAP in human cancers based on systematic analysis. Aging 2023;15:7056-83.
264. Martori C, Sanchez-Moral L, Paul T, et al. Macrophages as a therapeutic target in metastatic prostate cancer: a way to overcome immunotherapy resistance? Cancers 2022;14:440.
265. Gordon S, Plüddemann A. The mononuclear phagocytic system. generation of diversity. Front Immunol 2019;10:1893.
266. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 2014;6:13.
267. Das A, Sinha M, Datta S, et al. Monocyte and macrophage plasticity in tissue repair and regeneration. Am J Pathol 2015;185:2596-606.
269. He MX, Cuoco MS, Crowdis J, et al. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med 2021;27:426-33.
270. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005;175:342-9.
271. Li XF, Selli C, Zhou HL, et al. Macrophages promote anti-androgen resistance in prostate cancer bone disease. J Exp Med 2023:220.
272. Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov 2022;21:799-820.
273. Abram CL, Lowell CA. The diverse functions of Src family kinases in macrophages. Front Biosci 2008;13:4426-50.
274. Loi M, Salvatore G, Sottili M, et al. Tumor-associated macrophages (TAMs) modulate response to HER2-targeted agents in a humanized mouse model of breast cancer. Clin Transl Oncol 2022;24:1395-402.
275. Watanabe H, Ohashi K, Nishii K, et al. A long-term response to nivolumab in a case of PD-L1-negative lung adenocarcinoma with an EGFR mutation and surrounding PD-L1-positive tumor-associated macrophages. Intern Med 2019;58:3033-7.
276. Su S, Lei A, Wang X, et al. Induced CAR-macrophages as a novel therapeutic cell type for cancer immune cell therapies. Cells 2022;11:1652.
277. Liu M, Liu J, Liang Z, et al. CAR-macrophages and CAR-T cells synergistically kill tumor cells in vitro. Cells 2022;11:3692.
278. Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012;104:273-9.
279. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-80.
280. Tjoa B, Erickson S, Bowes V, et al. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 1997;32:272-8.
281. Jähnisch H, Füssel S, Kiessling A, et al. Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol 2010;2010:517493.
282. Kiessling A, Wehner R, Füssel S, Bachmann M, Wirth MP, Schmitz M. Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers 2012;4:193-217.
283. Kitamura H, Torigoe T, Asanuma H, Honma I, Sato N, Tsukamoto T. Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J Urol 2007;178:692-6.
284. Lozano M, Cid J, Benitez-Ribas D, Otero MJ. Technical challenges in the manufacture of dendritic cell cancer therapies. Eur Oncol Haematol 2019;15:22-8.
285. Kongsted P, Borch TH, Ellebaek E, et al. Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: a randomized phase II study. Cytotherapy 2017;19:500-13.
286. Glabman RA, Choyke PL, Sato N. Cancer-associated fibroblasts: tumorigenicity and targeting for cancer therapy. Cancers 2022;14:3906.
287. Boudewijns S, Westdorp H, Koornstra RH, et al. Immune-related adverse events of dendritic cell vaccination correlate with immunologic and clinical outcome in stage III and IV melanoma patients. J Immunother 2016;39:241-8.
